MGAT2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5856106	0.37	12/20
SCHEMBL5369910	0.55	7/20
SCHEMBL1818184	0.51	7/20
SCHEMBL646546	0.37	7/20
SCHEMBL850028	0.35	7/20
SCHEMBL850029	0.35	7/20
SCHEMBL7080677	0.37	6/20
SCHEMBL787778	0.35	6/20
SCHEMBL5855583	0.32	6/20
SCHEMBL5855586	0.32	6/20
SCHEMBL6566287	0.32	6/20
SCHEMBL5361704	0.57	5/20
SCHEMBL7136606	0.55	5/20
SCHEMBL1311942	0.55	5/20
SCHEMBL5357745	0.55	5/20
SCHEMBL5370423	0.54	5/20
SCHEMBL7136121	0.54	5/20
SCHEMBL7136258	0.54	5/20
SCHEMBL5363038	0.51	5/20
SCHEMBL7138959	0.51	5/20

Clinical trials — most relevant to MGAT2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta	PHASE4	COMPLETED
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)	PHASE3	COMPLETED
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	PHASE2	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)	PHASE2	COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3	PHASE2	NOT_YET_RECRUITING
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease	PHASE1/PHASE2	UNKNOWN
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy	PHASE2	UNKNOWN
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Oral OKT3 in Combination With Beta-D-Glucosylceramide	PHASE1	UNKNOWN
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
Effect of Migalastat on Cardiac Involvement in Fabry Disease	nan	COMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Biomarker for Glycogen Storage Diseases (BioGlycogen)	nan	WITHDRAWN
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MGAT2 binder may also engage these)

Protein	Name	Similarity
O19071	—	1.000	O19071 →
Q921V5	—	1.000	Q921V5 →
Q09326	—	0.998	Q09326 →
P15535	—	0.987	P15535 →
Q80WN9	—	0.985	Q80WN9 →
B4GALT1	Beta-1,4-galactosyltransferase 1	0.985	landscape →
Q7Z1Z1	—	0.984	Q7Z1Z1 →
Q17FB8	—	0.984	Q17FB8 →
Q9Z2Y2	—	0.984	Q9Z2Y2 →
Q9BRR3	—	0.983	Q9BRR3 →
A8Y1P7	—	0.983	A8Y1P7 →
Q5XIN7	—	0.982	Q5XIN7 →
Q66HH1	—	0.982	Q66HH1 →
Q29NU5	—	0.982	Q29NU5 →
Q9P2W7	—	0.981	Q9P2W7 →
L7YAI7	—	0.981	L7YAI7 →
Q8IPK4	—	0.981	Q8IPK4 →
Q5EA41	—	0.981	Q5EA41 →
Q5U3T0	—	0.981	Q5U3T0 →
Q8N428	—	0.981	Q8N428 →
Q11068	—	0.981	Q11068 →
Q8IXK2	—	0.981	Q8IXK2 →
Q9VYV5	—	0.981	Q9VYV5 →
GALNT10	Polypeptide N-acetylgalactosaminyltransferase 10	0.981	landscape →
E9Q649	—	0.981	E9Q649 →
Q8C7U7	—	0.981	Q8C7U7 →
Q5QQ53	—	0.981	Q5QQ53 →
O01705	—	0.981	O01705 →
Q6NQ51	—	0.980	Q6NQ51 →
Q765H6	—	0.980	Q765H6 →